Embryonic Regulation and Research: What Is the Status of Human Germline Genome Editing in Australia?
- 1 April 2020
- journal article
- research article
- Vol. 27 (3), 718-740
Abstract
This article considers the status of human germline genome editing in Australia. Through an analysis of the current State, Territory and Commonwealth legal and ethical regulatory frameworks, and incorporating the capability approach to health justice proposed by Martha Nussbaum and Amartya Sen, the article argues that heritable alterations using CRISPR/Cas9 technology in a clinical context are inevitable in Australia, so the law needs to respond adequately to these scientific advances. The article concludes that human germline genome editing is currently not, and should not, be lawful in Australia, except for research purposes.Keywords
This publication has 28 references indexed in Scilit:
- Development and Applications of CRISPR-Cas9 for Genome EngineeringCell, 2014
- A CRISPR Approach to Gene TargetingMolecular Therapy, 2012
- Human pre-implantation embryo developmentDevelopment, 2012
- Hydrogen and the 2050 UK energy consumerInternational Journal of Low-Carbon Technologies, 2011
- Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discoveryBJOG: An International Journal of Obstetrics and Gynaecology, 2008
- HEALTH, JUSTICE, AND THE ENVIRONMENTBioethics, 2007
- Creating and sacrificing embryos for stem cellsJournal of Medical Ethics, 2005
- Zygote transfer on day 1 versus cleavage stage embryo transfer on day 3: a prospective randomized trialHuman Reproduction, 2004
- CAPABILITIES AS FUNDAMENTAL ENTITLEMENTS: SEN AND SOCIAL JUSTICEFeminist Economics, 2003
- Why health equity?Health Economics, 2002